Bleeding disorder is a set of disorders, or disease which normally affect the process of clotting of our blood. This bleeding can be in many cases like during an accident, trauma condition, surgery, injury or a menstrual cycle. These bleeding disorders are not only associated with bloods leaving out from our body, rather it can also be an internal bleeding beneath our skin or brain. These may be hemophilia A and B or Willebrand’s disease for example. Sometimes this disease is also termed as royal disease.
The main symptom of bleeding disorder would be excessive bleeding and prolonged clotting time during normal injuries also. These can also easily identified by frequent nose bleeding, heavy menstrual bleeding and unexplained bruishing.
There are mainly two common type of instant treatment available for bleeding disorder, which is iron supplementation or clotting factor repalacement and blood transfusion. These are the therapeutic aspect, but extended research is in progress in various countries, where this disease has a greater prevalence rate.
According to a study in Germany, the prevalence of menorrhagia in women with VWD is 74-92%.The prevalence increases according to severity of VWD type, with a higher percentage in VWD type 3 than in types 1 and 2.9 Conversely, the prevalence of VWD in women with menorrhagia is 5-24%, with an overall prevalence of 13% (95% con- fidence interval [CI], 11-16%) based on a systematic review of 11 studies comprising 988 women with menorrhagia.10 Bleeding disorders, especially VWD with an incidence of approximately 1% in the general population,are therefore of notable concern in women with menorrhagia. VWD is an inherited disease, and although it affects male and female with equal frequency, women are more likely to manifest the disorder clinically because of the bleeding challenges that are associated with menstruation and childbirth.
Translational toolsas applicable to autoimmune disorders: antibody-proteases as a generation of highly informative and unique biomarkersto monitor subclinical and clinical stages of demyelination in multiple sclerosis (MS) PPT Version |